BPC-157 (5mg / 10mg)

BPC-157 Peptide (Body Protection Compound-157) – Research Overview

Body Protection Compound-157 (BPC-157), also classified as a pentadecapeptide due to its 15 amino acid sequence, is a synthetic peptide derived from an active protective factor isolated from human gastric juice.

Extensively studied within regenerative medicine, BPC-157 acts as a multi-tissue cytoprotective agent. Preclinical models demonstrate its pronounced efficacy in accelerating the repair of complex musculoskeletal soft tissues (tendons, ligaments, and skeletal muscles), stabilizing compromised gastrointestinal mucosa, and modulating neurotransmitter systems.

Quick Chemical Profile

• Molecular Formula: $C_{62}H_{98}N_{16}O_{22}$

• Molecular Weight: 1419.55 g/mol

• Sequence: 15 Amino Acid Fragment

• Synonyms: Pentadecapeptide BPC-157, PL-10, Body Protection Compound-157

• Application: Laboratory Research Use Only

Primary Research & Clinical Insights

1. Angiogenesis and Accelerated Wound Healing

Preclinical investigations across diverse tissue injury models indicate that BPC-157 serves as a robust catalyst for systemic tissue remodeling:

• Growth Factor Up-regulation: BPC-157 cross-activates growth hormone (GH) receptors and significantly enhances the expression of vascular endothelial growth factor A (VEGF-a). This triggers rapid cell proliferation and neoangiogenesis (the formation of new blood vessel networks).

• Endothelial Cell Dynamics: In vitro assays utilizing Human Umbilical Vein Endothelial Cells (HUVECs) demonstrate that the peptide increases both the migration rate and the assembly speed of vascular tubes.

• Intracellular Signaling Modulation: BPC-157 regulates the phosphorylation (chemical activation) of extracellular signal-regulated kinases 1 and 2 (ERK1/2). This activates downstream transcription targets including c-Fos, c-Jun, and Egr-1, which control cellular migration, dermal remodeling, and structural collagen deposition.

2. Musculoskeletal and Tendon Fibroblast Repair

Unlike standard growth factors that exhibit localized efficacy, BPC-157 drives systemic functional recovery in damaged tendons, ligaments, and bone fractures:

• The FAK-Paxillin Pathway: In cultured tendon fibroblasts, the peptide induces high-level phosphorylation of Focal Adhesion Kinase (FAK) and paxillin without altering total protein volume. This directly promotes cell adhesion, cytoskeletal organization, and targeted migration to the site of injury via F-actin formation.

• Corticosteroid Mitigation: Systemic corticosteroid application is clinically proven to degrade muscle tissue and stall recovery. In murine models with gastrocnemius muscle damage complicated by methylprednisolone use, BPC-157 completely counteracted corticosteroid-induced muscle atrophy, restoring native functional capacity and tissue architecture.

3. Gastrointestinal Cytoprotection & Peptidergic Defense

As a gastric-derived compound, BPC-157 shows remarkable structural stability in acidic environments, outperforming standard angiogenic factors like EGF and FGF across chronic and acute lesions:

• Organ-Wide Lesion Reversal: Research verifies consistent mucosal healing across the entire alimentary tract, successfully resolving ulcerations in the esophagus, stomach, duodenum, lower GI tract, and pancreas.

• Neurotransmitter Balancing: BPC-157 interfaces with the body’s endogenous peptidergic defense systems. It counteracts systemic inflammation and organ lesions caused by the over-activation or inhibition of the dopamine, nitrous oxide (NO), prostaglandin, and somatosensory neuron pathways.

• Serotonergic Modulation: By counteracting 5-HT2A receptors, the peptide restricts excessive serotonin binding within the GI mucosa, thereby stabilizing gastric blood flow and regulating acid secretion.

4. Central Nervous System Protection & Neurological Modulation

Emerging research reveals that BPC-157 crosses the blood-brain barrier to exert profound neuroprotective and behavioral effects:

• Traumatic Brain Injury (TBI) Mitigation: In force-impulse simulated TBI models, administration of BPC-157 significantly decreased post-injury mortality within the critical 24-hour window. Histological examinations showed a marked reduction in severe traumatic lesions, including subarachnoid and intraventricular hemorrhages, brain lacerations, and tissue edema (swelling).

• Dopaminergic System Regulation: The peptide demonstrates a clear stabilizing effect on dopamine receptors. In laboratory settings, BPC-157 effectively reverses amphetamine-induced hyper-excitability (dopamine agonist activity) while simultaneously blocking haloperidol-induced dopaminergic supersensitivity.

Why Choose Us for BPC-157 Peptide?

When looking to buy BPC-157 research peptide materials, securing chemical purity and batch-to-batch consistency is vital for maintaining experimental integrity.

• Verified Purity Profiles: All analytical compounds undergo rigorous HPLC (High-Performance Liquid Chromatography) and mass spectrometry validation to ensure exact molecular weight and structural sequence mapping.

• Lyophilization Superiority: Our peptides are synthesized using advanced freeze-drying protocols to eliminate moisture contamination, ensuring maximum stability during transit and storage.

• Global Research Support: We provide secure, climate-controlled logistics to preserve compound viability from our laboratory directly to your research facility.

For validated high-purity compounds, secure documentation, and optimized ordering configurations, visit Peptide Shop AU.

Section 621 Disclaimer

BPC-157 is available strictly for research and laboratory purposes only. It is not approved for human consumption, diagnostic, therapeutic, or clinical use. Please thoroughly review and adhere to our verified Terms and Conditions before completing your order.

Referenced Literature

1. Chang, C. H., et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774-80.

2. Ormsbee, H. S. 3rd, & Fondacaro, J. D. (1985). Action of serotonin on the gastrointestinal tract. Proceedings of the Society for Experimental Biology and Medicine, 178(3), 333-8.

3. Sikiric, P., et al. (2016). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology, 14(8), 857-865.

4. Krivic, A., et al. (2008). Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflammation Research, 57, 205–210.

5. Seiwerth, S., et al. (1997). BPC 157’s effect on healing. Journal of Physiology, Paris, 91(3-5), 173-8.

6. Huang, T., et al. (2015). Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Design, Development and Therapy, 9, 2485–2499.

7. Seiwerth, S., et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design, 24(18), 1972-1989.

8. Sikiric, P. (1999). The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology, 7(1), 1–14.

9. Pevec, D., et al. (2010). Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical Science Monitor, 16(3), BR81-88.

10. Jelovac, N., et al. (1998). A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. Biological Psychiatry, 43(7), 511-9.

11. Tudor, M., et al. (2010). Traumatic brain injury in mice and the effect of pentadecapeptide BPC 157. Regulatory Peptides, 160(1-3), 26–32.

Medical Reviewer: Dr. Marinov (MD, PhD), Chief Assistant Professor in Preventive Medicine & Public Health. Specialist in Evidence-Based Medicine, Angiogenesis, and Peptidergic Cytoprotection.